Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Vimpat
Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-119442 · Präparat HOS-094947
Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent.
Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given
200 mg twice a day), but C max of midazolam was slightly increased (30 %). Lacosamide did not affect
the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given
300 mg twice a day).
The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant
change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic
lacosamide exposure to a clinically relevant extent.
Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.
fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead
to increased systemic exposure of lacosamide. Such interactions have not been established in vivo, but
are possible based on in vitro data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage 306c6e516bd92e26230e3ed678f84de0363304e5a11ec579daa8f9588f965831 · Zeichen 998–1964 im Abschnitt
Wechselwirkungen · Vimpat
Treatment initiation pack (in adolescents and children weighing 50 kg or more and adults only) Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 27
HOS-119477 · Präparat HOS-094947
Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent.
Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given
200 mg twice a day) but C max of midazolam was slightly increased (30 %). Lacosamide did not affect
the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given
300 mg twice a day).
The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant
change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic
lacosamide exposure to a clinically relevant extent.
Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.
fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead
to increased systemic exposure of lacosamide. Such interactions have not been established in vivo but
are possible based on in vitro data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage 09bdb85e3781a2bbf9800b7cbb7cfaaa50df0c6d9f79307fa9fb41425f2e39dc · Zeichen 998–1962 im Abschnitt
Wechselwirkungen · Vimpat
Vimpat 10 mg/ml syrup · Abschnitt 4.5 · PDF-Seite 49
HOS-119510 · Präparat HOS-094947
Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent.
Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given
200 mg twice a day) but C max of midazolam was slightly increased (30 %). Lacosamide did not affect
the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given
300 mg twice a day).
The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant
change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic
lacosamide exposure to a clinically relevant extent.
Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.
fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead
to increased systemic exposure of lacosamide. Such interactions have not been established in vivo but
are possible based on in vitro data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage 09bdb85e3781a2bbf9800b7cbb7cfaaa50df0c6d9f79307fa9fb41425f2e39dc · Zeichen 998–1962 im Abschnitt
Wechselwirkungen · Vimpat
Vimpat 10 mg/ml solution for infusion · Abschnitt 4.5 · PDF-Seite 70
HOS-119545 · Präparat HOS-094947
Lacosamide does not inhibit or induce CYP2C19 and CYP3A4 to a clinically relevant extent.
Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given
200 mg twice a day) but C max of midazolam was slightly increased (30 %). Lacosamide did not affect
the pharmacokinetics of omeprazole (metabolised by CYP2C19 and CYP3A4, lacosamide given
300 mg twice a day).
The CYP2C19 inhibitor omeprazole (40 mg once daily) did not give rise to a clinically significant
change in lacosamide exposure. Thus, moderate inhibitors of CYP2C19 are unlikely to affect systemic
lacosamide exposure to a clinically relevant extent.
Caution is recommended in concomitant treatment with strong inhibitors of CYP2C9 (e.g.
fluconazole) and CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, clarithromycin), which may lead
to increased systemic exposure of lacosamide. Such interactions have not been established in vivo but
are possible based on in vitro data.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) lead (HOS-085592) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) ritonavir (HOS-084521) midazolam (HOS-086167) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-20T11:46:00Z · SHA-256 5f9684302e7c8a579e94d70f499a6979b21c5d712f752fe49c5607a3581bef64 · Passage 09bdb85e3781a2bbf9800b7cbb7cfaaa50df0c6d9f79307fa9fb41425f2e39dc · Zeichen 1058–2022 im Abschnitt
Wechselwirkungen · Intelence
INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-119739 · Präparat HOS-095005
10
Clarithromycin clarithromycin Clarithromycin exposure was
500 mg twice daily AUC ↓ 0.61 (0.53-0.69) decreased by etravirine;
Cmin ↓ 0.47 (0.38-0.57) however, concentrations of
Cmax ↓ 0.66 (0.57-0.77) the active metabolite,
14-OH-clarithromycin 14-OH-clarithromycin, were
AUC ↑ 1.21 (1.05-1.39) increased. Because
Cmin ↔ 1.05 (0.90-1.22) 14-OH-clarithromycin has
Cmax ↑ 1.33 (1.13-1.56) reduced activity against
etravirine Mycobacterium avium
AUC ↑ 1.42 (1.34-1.50) complex (MAC), overall
Cmin ↑ 1.46 (1.36-1.58) activity against this pathogen
Cmax ↑ 1.46 (1.38-1.56) may be altered; therefore
alternatives to clarithromycin
should be considered for the
treatment of MAC.
ANTICOAGULANTS
Warfarin Not studied. Etravirine is expected to increase It is recommended that the
plasma concentrations of warfarin. international normalised ratio
(INR) be monitored when
warfarin is combined with
INTELENCE.
ANTICONVULSANTS
Carbamazepine Not studied. Carbazamepine, phenobarbital and Combination not
Phenobarbital phenytoin are expected to decrease plasma recommended.
Phenytoin concentrations of etravirine.
ANTIFUNGALS
Fluconazole fluconazole INTELENCE and
200 mg once in the AUC ↔ 0.94 (0.88-1.01) fluconazole can be used
morning Cmin ↔ 0.91 (0.84-0.98) without dose adjustments.
Cmax ↔ 0.92 (0.85-1.00)
etravirine
AUC ↑ 1.86 (1.73-2.00)
Cmin ↑ 2.09 (1.90-2.31)
Cmax ↑ 1.75 (1.60-1.91)
Itraconazole Not studied. Posaconazole, a potent inhibitor of INTELENCE and these
Ketoconazole CYP3A4, may increase plasma concentrations antifungals can be used
Posaconazole of etravirine. Itraconazole and ketoconazole are without dose adjustments.
potent inhibitors as well as substrates of
CYP3A4. Concomitant systemic use of
itraconazole or ketoconazole and etravirine may
increase plasma concentrations of etravirine.
Simultaneously, plasma concentrations of
itraconazole or ketoconazole may be decreased
by etravirine.
Voriconazole voriconazole INTELENCE and
200 mg twice daily AUC ↑ 1.14 (0.88-1.47) voriconazole can be used
Cmin ↑ 1.23 (0.87-1.75) without dose adjustments.
Cmax ↓ 0.95 (0.75-1.21)
etravirine
AUC ↑ 1.36 (1.25-1.47)
Cmin ↑ 1.52 (1.41-1.64)
Cmax ↑ 1.26 (1.16-1.38)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) voriconazole (HOS-084524) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) phenytoin (HOS-084531) warfarin (HOS-085950) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-13T16:37:00Z · SHA-256 b6b2c3fd3d600c0f1fd17ddc8f6c1da50bcb8b2181089113d0397c5ec46864c4 · Passage f2c0b518e46b49380453d42466b01a8fff3ee9fcf4e19d11338666ec48a74869 · Zeichen 16178–20124 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-120046 · Präparat HOS-095079
Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold
increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with
fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-
risk patients. (For patients with renal impairment: see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 5a4fe991884a52803c81e576328fdc273a82450691a257c7a8a1ea7141e82051 · Zeichen 2041–2403 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-120079 · Präparat HOS-095079
Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold
increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with
fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-
risk patients. (For patients with renal impairment: see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 5a4fe991884a52803c81e576328fdc273a82450691a257c7a8a1ea7141e82051 · Zeichen 2097–2459 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62
HOS-120110 · Präparat HOS-095079
Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold
increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with
fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-
risk patients. (For patients with renal impairment: see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 5a4fe991884a52803c81e576328fdc273a82450691a257c7a8a1ea7141e82051 · Zeichen 2321–2683 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94
HOS-120142 · Präparat HOS-095079
Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold
increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with
fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-
risk patients. (For patients with renal impairment: see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 5a4fe991884a52803c81e576328fdc273a82450691a257c7a8a1ea7141e82051 · Zeichen 2321–2683 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets Xarelto 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 124
HOS-120173 · Präparat HOS-095079
Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold
increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with
fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-
risk patients. (For patients with renal impairment: see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 5a4fe991884a52803c81e576328fdc273a82450691a257c7a8a1ea7141e82051 · Zeichen 2099–2461 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 1 mg/mL granules for oral suspension · Abschnitt 4.5 · PDF-Seite 149
HOS-120204 · Präparat HOS-095079
Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold
increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax. The interaction with
fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-
risk patients. (For patients with renal impairment: see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 5a4fe991884a52803c81e576328fdc273a82450691a257c7a8a1ea7141e82051 · Zeichen 2321–2683 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 11–12
HOS-209751 · Präparat HOS-154375
11
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
The effect on tacrolimus
blood concentrations may
remain for several days after
co-administration is
completed.
Moderate or weak CYP3A4 May increase tacrolimus Monitor tacrolimus whole blood
inhibitors: whole blood trough trough concentrations frequently,
antifungal agents (e.g., concentrations and increase starting within the first few days
fluconazole, isavuconazole, the risk of serious adverse of co-administration. Reduce
clotrimazole, miconazole), reactions (e.g., neurotoxicity, tacrolimus dose if needed [see
the macrolide antibiotics QT prolongation) [see section 4.2]. Monitor renal
(e.g., azithromycin), calcium section 4.4]. A rapid increase function, ECG for QT
channel blockers (e.g., in tacrolimus level may prolongation, and other side
nifedipine, nicardipine, occur. effects closely.
diltiazem, verapamil),
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
In vitro the following May increase tacrolimus Monitor tacrolimus whole blood
substances have been shown whole blood trough trough concentrations and reduce
to be potential inhibitors of concentrations and increase tacrolimus dose if needed [see
tacrolimus metabolism: the risk of serious adverse section 4.2].
bromocriptine, cortisone, reactions (e.g., neurotoxicity, Monitor renal function, ECG for
dapsone, ergotamine, QT prolongation) [see QT prolongation, and other side
gestodene, lidocaine, section 4.4]. effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus It is recommended that
rifampicin, phenytoin whole blood trough concomitant use should be
carbamazepine, apalutamide, concentrations and increase avoided. If unavoidable, patients
enzalutamide, mitotane or St. the risk of rejection [see may require an increase in
John’s wort (Hypericum section 4.4]. tacrolimus dose. Changes in
perforatum) Maximal effect on tacrolimus tacrolimus dose should be
blood concentrations may be individualized and adjusted as
achieved 1-2 weeks after co- needed based on tacrolimus
administration. The effect trough concentrations, which
may remain 1-2 weeks after should be assessed at initiation,
completion of the treatment. monitored frequently throughout
(starting within the first few days)
and re-evaluated on and after
completion of the CYP3A4
inducer. After use of the CYP3A4
inducer has ended, tacrolimus
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) diltiazem (HOS-086288) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) cortisone (HOS-114161) nicardipine (HOS-090619) pibrentasvir (HOS-086298) lidocaine (HOS-108866) carbamazepine (HOS-085618) crizotinib (HOS-116818) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) mephenytoin (HOS-109801) calcium (HOS-085615) imatinib (HOS-110212) grazoprevir (HOS-108815) danazol (HOS-085473) mitotane (HOS-112479) fluconazole (HOS-087945) bromocriptine (HOS-090620) nilvadipine (HOS-116826) gestodene (HOS-116824) ergotamine (HOS-086154) amiodarone (HOS-085596) tyrosine (HOS-108875) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) nilotinib (HOS-086218) miconazole (HOS-115630) midazolam (HOS-086167) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 1e7cc303a6d0d182851c23281c6a79a17f96d714a9cddc0ab3d6ada78ab947ab · Zeichen 6985–10993 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7
HOS-120558 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms nasal spray, solution in single-dose container Instanyl 100 micrograms nasal spray, solution in single-dose container Instanyl 200 micrograms nasal spray, solution in single-dose container · Abschnitt 4.5 · PDF-Seite 20
HOS-120583 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 33
HOS-120606 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Clopidogrel Zentiva (previously Clopidogrel Winthrop)
Clopidogrel Zentiva 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-209889 · Präparat HOS-154399
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) carbamazepine (HOS-085618) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) fluoxetine (HOS-085946) efavirenz (HOS-087947) fluvoxamine (HOS-085908) ticlopidine (HOS-087946) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-03T16:45:00Z · SHA-256 e0215a720388221c98b7ac2dbc71d7bb651807eaa839c43dbd3c29e450499ab6 · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4148–4372 im Abschnitt
Wechselwirkungen · Afinitor
Afinitor 2.5 mg tablets Afinitor 5 mg tablets Afinitor 10 mg tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-210305 · Präparat HOS-154501
Active substance by Interaction – Change in Recommendations concerning
interaction Everolimus AUC/Cmax co-administration
Geometric mean ratio
(observed range)
Potent CYP3A4/PgP inhibitors
Ketoconazole AUC ↑15.3-fold Concomitant treatment of Afinitor
(range 11.2-22.5) and potent inhibitors is not
Cmax ↑4.1-fold recommended.
(range 2.6-7.0)
Itraconazole, posaconazole, Not studied. Large increase in
voriconazole everolimus concentration is
Telithromycin, expected.
clarithromycin
Nefazodone
Ritonavir, atazanavir,
saquinavir, darunavir,
indinavir, nelfinavir
Moderate CYP3A4/PgP inhibitors
Erythromycin AUC ↑4.4-fold Use caution when
(range 2.0-12.6) co-administration of moderate
Cmax ↑2.0-fold CYP3A4 inhibitors or PgP
(range 0.9-3.5) inhibitors cannot be avoided. If
Imatinib AUC ↑ 3.7-fold patients require co-administration
Cmax ↑ 2.2-fold of a moderate CYP3A4 or PgP
Verapamil AUC ↑3.5-fold inhibitor, dose reduction to 5 mg
(range 2.2-6.3) daily or 2.5 mg daily may be
Cmax ↑2.3-fold considered. However, there are no
(range1.3-3.8) clinical data with this dose
Ciclosporin oral AUC ↑2.7-fold adjustment. Due to between
(range 1.5-4.7) subject variability the
Cmax ↑1.8-fold recommended dose adjustments
(range 1.3-2.6) may not be optimal in all
Cannabidiol (PgP inhibitor) AUC ↑2.5-fold individuals, therefore close
Cmax ↑2.5-fold monitoring of side effects is
Fluconazole Not studied. Increased exposure recommended (see sections 4.2 and
Diltiazem expected. 4.4). If the moderate inhibitor is
Dronedarone Not studied. Increased exposure discontinued, consider a washout
expected. period of at least 2 to 3 days
Amprenavir, fosamprenavir Not studied. Increased exposure (average elimination time for most
expected. commonly used moderate
inhibitors) before the Afinitor dose
is returned to the dose used prior to
initiation of the co-administration.
Grapefruit juice or other Not studied. Increased exposure Combination should be avoided.
food affecting CYP3A4/PgP expected (the effect varies
widely).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) atazanavir (HOS-086180) nelfinavir (HOS-084520) dronedarone (HOS-086144) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) cannabidiol (HOS-090609) imatinib (HOS-110212) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-20T11:21:00Z · SHA-256 678fc33837cd44d2e9320c5c80ffc02496b10803d7810e1b4f6e2d8e517263a0 · Passage 98d9f664e41c1a110308717f9cdec97f696053564a7a56a6d0f4d257ec0e0700 · Zeichen 1007–4534 im Abschnitt
Wechselwirkungen · Clopidogrel Teva (hydrogen sulphate)
Clopidogrel Teva 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-210569 · Präparat HOS-154547
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) carbamazepine (HOS-085618) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) fluoxetine (HOS-085946) efavirenz (HOS-087947) fluvoxamine (HOS-085908) ticlopidine (HOS-087946) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T12:25:00Z · SHA-256 2668df6ec61f9f4f66d3079105d2dc6c533c7c482102d41117d3a9ecab3c3583 · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4156–4380 im Abschnitt
Wechselwirkungen · Clopidogrel Krka
Clopidogrel Krka 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-210633 · Präparat HOS-154555
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) carbamazepine (HOS-085618) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) fluoxetine (HOS-085946) efavirenz (HOS-087947) fluvoxamine (HOS-085908) ticlopidine (HOS-087946) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-14T09:49:00Z · SHA-256 de285f540dd9461c605738f58c4125215a83fbcefb35a3be3d9119eb1b2b68a9 · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4156–4380 im Abschnitt
Wechselwirkungen · Zyllt
Zyllt 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-121544 · Präparat HOS-095389
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole
and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine,
carbamazepine, and efavirenz.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): esomeprazole (HOS-087944) carbamazepine (HOS-085618) moclobemide (HOS-087879) voriconazole (HOS-084524) fluconazole (HOS-087945) fluoxetine (HOS-085946) efavirenz (HOS-087947) fluvoxamine (HOS-085908) ticlopidine (HOS-087946) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-14T12:07:00Z · SHA-256 f7bf5ef29f88fd676dd0507812419bb944fe4584c2c7bb6fde3ba14cc8084d6f · Passage 6adad8692c6fecb943bf126bdc5047021725d2d6aca1b2738e493857127bf04c · Zeichen 4156–4380 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.